Tag: aromataseInhibitors
Articles
News
Foods
Studies
- Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study
- Adjuvant Hormonal Therapy for Breast Cancer and Risk of Hormone Receptor-Specific Subtypes of Contralateral Breast Cancer
- Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer
- An analysis of vitamin D (Vit D) and serum estrogens in postmenopausal (PM) breast cancer (BC) patients receiving aromatase inhibitors (AIs)
- Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients
- Aromatase inhibitor and tamoxifen's impact on breast cancer recurrence among survivors in a large HMO
- Aromatase Inhibitors as Solely Treatment in Postmenopausal Breast Cancer Patients
- Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers
- Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer
- Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial
- Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer
- Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
- Breast cancer in the very elderly: Staging, treatment, and outcomes in patients over age 80
- Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer
- Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2—3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study
- Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial
- Changes in Weight and Body Composition in Women Receiving Chemotherapy for Breast Cancer
- Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole
- Deep Time: The Long and the Short of Adjuvant Endocrine Therapy for Breast Cancer
- Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo
- Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?
- Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy
- Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study
- Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma
- Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole
- Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial
- Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial
- Effect of early discontinuation and nonadherence to adjuvant hormone therapy on mortality in women with breast cancer
- Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer
- Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial
- Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a Selective Estrogen Receptor Modulator
- Eligibility, compliance and persistence of extended adjuvant endocrine therapy for breast cancer
- Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle
- Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer
- Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D
- Evaluating Letrozole and Tamoxifen Alone and in Sequence at 8 Years Median Follow-up for Postmenopausal Women With Steroid Hormone Receptor-Positive Breast Cancer
- Final 5-year results of Z-FAST trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole
- Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model
- HDAC inhibitors trigger the autophagic switch from prosurvival to prodeath in tamoxifen-treated breast cancer cells
- Hormone Treatment without Surgery for Patients Aged 75 Years or Older with Operable Breast Cancer
- Induced sex reversal using an aromatase inhibitor, Fadrozole, in Atlantic halibut (Hippoglossus hippoglossus L.)
- Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer
- Invasive lobular carcinoma: response to neoadjuvant letrozole therapy
- Long-term (37 years) clinical outcome of older women with early operable primary breast cancer managed in a dedicated clinic
- Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation
- Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre
- Management of Hot Flashes in Patients Who Have Breast Cancer With Venlafaxine and Clonidine: A Randomized, Double-Blind, Placebo-Controlled Trial
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
- Molecular Pathways: Digoxin use and the estrogen-sensitive cancers: risks and possible therapeutic implications
- Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark
- Obesity Is Associated with Inflammation and Elevated Aromatase Expression in the Mouse Mammary Gland
- Obesity Linked to Worse Outcomes in Early Breast Cancer Treatment
- Patient-Reported Predictors of Early Treatment Discontinuation: NCIC JMA.27/E1Z03 Quality of Life Study of Postmenopausal Women with Primary Breast Cancer Randomized to Exemestane or Anastrozole
- Red Versus White Wine as a Nutritional Aromatase Inhibitor in Premenopausal Women
- Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer
- Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients
- Risk of second breast cancer according to estrogen receptor status and family history
- Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)
- Sexual Function after Breast Cancer
- Side effects associated with aromatase inhibitor treatment among breast cancer patients
- Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
- Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group
- The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study
- The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors
- The Protective Effect of Zoledronic Acid on Bone Loss in Postmenopausal Women with Early Breast Cancer Treated with Sequential Tamoxifen and Letrozole: A Prospective, Randomized, Phase II Trial
- Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
- Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial
- Vitamin D Deficiency in Post-Menopausal Breast Cancer Survivors
- Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study
- Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer
- Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors
- Zoledronic Acid Shows Long-Term Benefit in Survivorship for Premenopausal ER-Positive Breast Cancer